Brief · Use case · Clinical Operations
Enrollment Completion Outlook.
LiveOutlookProject whether a Phase 3 trial reaches its enrollment target by a stated date, from the current pace and the base rate for comparable trials.
Enrollment Completion Outlook is a ready-made use case for Clinical Operations. It ships under the Outlook template.
For clinical operations leads managing a timeline. You get the projected event and resolution test, the reference class for comparable trials, a central path with a range, scenarios and early signposts. Claims are cited or marked as gaps.
Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.
The decision
Will a Phase 3 trial in moderate-to-severe atopic dermatitis reach its enrollment target by a stated date, given the current pace, and how likely is it?
What the outlook examines
Enrollment is a rate, and the outlook extrapolates a rate. It also asks how often trials fail to reach their targets at all.
| Part of the outlook | What it asks | Where it looks |
|---|---|---|
| The current pace | Patients randomized per site per month, and the number of sites open, extended to the stated date. The central path and its range come from the pace over recent months. | The trial’s own enrollment data. |
| How often trials fall short | A study of trials with posted results in ClinicalTrials.gov found that about 12 percent had been terminated, and that for most of those the reason was not the trial’s data, with insufficient accrual the most common reason among them.1 | Williams and colleagues, 2015. |
| What is changing around the trial | Competing trials and sites, visible in the trial registers, and any remedy under way.2 | ClinicalTrials.gov and the EU Clinical Trials Information System. |
What the outlook does
A base rate for falling short. In the 2015 analysis, 905 of 7,646 trials with results posted, about 12 percent, were terminated; 68 percent of those were terminated for reasons other than the trial’s data, and insufficient accrual was the most common, at 57 percent of those. The outlook cites this as a reference class for trials that end early, and says it concerns trials with posted results, not all trials.1
A range, not a date. The central path is the date at the current pace. The low and high paths use the slowest and fastest recent months. The outlook gives the likelihood of reaching the target by the stated date from the share of that range that falls before it.
Signposts. The outlook names the signs that would change the path early: site activations, the screen-failure rate, a competing trial opening at the same sites, and a change in the protocol.2
Resolution. The question resolves when the trial’s own records show randomization of the target number, on or before the stated date.
Recommended length
Standard
One path dominates the question. Standard carries the projection, the base rate, the path, the drivers and the signposts in about 1,200 words.
You can pick another length on the form. The other two stay available.
Assumptions the outlook checks
The outlook states the assumptions its likelihood rests on and names the weakest one. Examples for this question:
- The recent pace is representative of the months to come.
- The number of open sites will not fall.
- No competing trial will open at the same sites.
Standards, guidance and sources
Reference classes and registers
The decision practice behind the memo itself is on the template page.
What gets flagged
Any assumption about pace that the data do not support, any competing trial the outlook found, and any use of the 2015 reference class as a prediction for this trial.
What arrives
- The projection
- Starting point and base rate
- What is already in motion
- The most likely path
- Scenarios
- What would change it
- Signposts
- Confidence, and where it is weakest
What it will not do
It does not predict with certainty or recommend an action. The likelihood carries a range, confidence is stated separately, and a Decision Memo uses the outlook as an input.
It does not recommend changes to the trial. A Diagnosis and a Plan do that work.
It does not predict with certainty. A likelihood is a statement about the evidence, with a range, and the outlook says how sure it is separately.
It does not make a base rate from nothing. Where no reference class exists, the base rate table says so and the likelihood is labeled analyst judgment.
It does not recommend an action. A Decision Memo takes the outlook as an input.
References
- [1] Williams, R. J., Tse, T., DiPiazza, K. and Zarin, D. A. Terminated trials in the ClinicalTrials.gov results database: evaluation of availability of primary outcome data and reasons for termination. PLOS ONE, 2015. DOI 10.1371/journal.pone.0127242. Figures as given in search excerpts: 905 of 7,646 trials terminated; 619 not for the data; 350 for insufficient accrual. Trials with results posted as of February 2013.
- [2] U.S. National Library of Medicine, ClinicalTrials.gov; European Medicines Agency, Clinical Trials Information System (CTIS) public site. Search on a stated date; results change.
Links checked 9 October 2026
These are the sources the template drew on. None of their authors or issuers has reviewed it.
About the Brief service
A Brief is a written answer from one specialist, at the depth you asked for. It arrives with its sources, and it closes by saying plainly what would change the conclusion. Nothing is hidden behind a summary, and anything the expert could not source is marked as a gap rather than filled in.
To edit a saved template, open New → Brief → From template, or the library rail on the service form.